RESUMEN
Total parenteral nutrition may be considered for a carefully selected group of palliative patients with ileus. Predictive factors include a strong desire to live, low burden of disease other than the ileus and expected increase in quality of life as a result of starting with total parenteral nutrition. Therapy compliance is required and a strong social network is desirable. Close collaboration between hospital and general practitioners and frequent reviews of the palliative care plan are also required for success.
Asunto(s)
Ileus/terapia , Enfermedades Intestinales/terapia , Cuidados Paliativos/métodos , Nutrición Parenteral Total/métodos , Femenino , Humanos , Ileus/psicología , Enfermedades Intestinales/psicología , Masculino , Cuidados Paliativos/psicología , Nutrición Parenteral Total/psicología , Cooperación del Paciente , Calidad de Vida , Apoyo SocialRESUMEN
Immune therapy is increasingly used as an effective treatment for various types of cancer. The response of tumours to immune therapy is different from conventional chemotherapy. In about 10% of patients, pseudoprogression may occur. This is a phenomenon where disease progression initially appears on imaging due to inflammation, but response is seen with repeated imaging. Pseudoprogression is often accompanied by a good clinical status. We describe a 63-year-old woman with metastasized melanoma, a 53-year-old woman with metastasized lung cancer and a 77-year-old woman with metastasized renal cancer who all developed pseudoprogression upon treatment with immune therapy. Premature discontinuation of treatment should be prevented when suspecting pseudoprogression and care should be taken to avoid burdening patients with bad news. Imaging should be repeated after a minimum interval of four weeks if pseudoprogression is suspected. When in doubt, a biopsy may be performed.
Asunto(s)
Neoplasias Encefálicas/patología , Inmunoterapia/efectos adversos , Neoplasias Pulmonares/terapia , Melanoma/patología , Anciano , Neoplasias Encefálicas/terapia , Progresión de la Enfermedad , Femenino , Humanos , Neoplasias Pulmonares/patología , Melanoma/terapia , Persona de Mediana Edad , Resultado del TratamientoRESUMEN
Immunotherapy induces a response against cancer by activating the immune system. Examples are therapies with checkpoint inhibitors, oncolytic viruses and chimeric antigen receptor T-cells (CAR T-cells). These therapies have, due to their rapid development, found their way to daily practice. For some patients with metastatic disease immunotherapy has led to significant long-term survival. Currently, there is a shift in the treatment with checkpoint inhibitors towards the (neo)adjuvant setting. Treatments with CAR T-cells seem particularly effective in haematological malignancies. Oncolytic viruses are used in the treatment for melanoma, but presently only on a limited scale. Only a limited number of patients benefit from immunotherapy. There remain many challenges for the future, most importantly the optimal use of treatment, recognition and treatment of side effects, determining the optimal duration of treatment and the increasing healthcare costs.